As new methods of delivering and administering glucagon are created, including bihormonal hybrid closed—loop devices, these data offer justification and rationale for using glucagon in managing hypoglycemia during fasting periods in individuals with T1D. Here, GCG is linked to type 1 diabetes mellitus.